Pre-Made Denileukin Diftitox Biosimilar, Fusion Protein targeting IL1RL2 fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting IL-1Rrp2/IL-36R/IL1R-rp2/IL1RRP2 for drug discovery and mechanism of action (MOA) research

Pre-Made Denileukin Diftitox Biosimilar, Fusion Protein targeting IL1RL2 fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting IL-1Rrp2/IL-36R/IL1R-rp2/IL1RRP2 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Denileukin diftitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining interleukin-2 and diphtheria toxin. Denileukin diftitox could bind to interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some leukemias and lymphomas, malignant cells express these receptors, so denileukin diftitox can target these.

Denileukin diftitox is a recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor. Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-799-1mg	1mg	3090
GMP-Bios-INN-799-10mg	10mg	Inquiry
GMP-Bios-INN-799-100mg	100mg	Inquiry
GMP-Bios-INN-799-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Denileukin Diftitox Biosimilar, Fusion Protein targeting IL1RL2 fused with human IL2 (interleukin 2, IL-2): Recombinant therapeutic protein targeting IL-1Rrp2/IL-36R/IL1R-rp2/IL1RRP2
INN Name	Denileukin Diftitox
Target	IL1RL2
Format	Fusion Protein
Derivation	Corynebacterium diphtheriae human
Species Reactivity	human
CH1 Isotype	Fusion - aldifitox : diphteriatoxin (AB toxin) 1-387 - IL2 (interleukin 2, IL-2) 1-133
VD LC	Fusion - aldifitox : diphteriatoxin (AB toxin) 1-387 - IL2 (interleukin 2, IL-2) 1-133
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Eisai Co. Ltd. (Tokyo Japan)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0